Background: Prognosis of distal cholangiocarcinoma (DCC) after pancreaticoduodenectomy (PD) remains poorly assessed. The aims of this study were to describe the oncological results of PD in DCC and to compare its prognosis to pancreatic ductal adenocarcinoma (PDAC).
Methods: All PD for periampullary carcinoma performed between January 2000 and March 2013 were extracted from a prospective database. Risk factors likely to influence overall (OS) and disease-free (DFS) survivals of DCC were assessed by multivariable analyses. The DCC and PDAC prognoses were compared after matching using propensity score (nearest neighbor matching).
Results: Of the 290 patients analyzed, 56 had DCC, with a mean age of 65 ± 15 years. The median OS was 36.9 months. Recurrence occurred in 35 patients (67%), mostly in the liver (37%). The median DFS was 14.6 months. Combined organ resection was an independent risk factor for worse OS and DFS (P = 0.01 and P = 0.001, respectively). Matching analysis found no significant difference between DCC and PDAC in terms of OS (P = 0.284) or DFS (P = 0.438).
Conclusion: This first propensity analysis demonstrated that DCC and PDAC have the same prognosis, linked to the high rate of early recurrence, particularly associated with the need for combined organ resection. J. Surg. Oncol. 2016;113:575-580. © 2016 Wiley Periodicals, Inc.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.24165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study.
Clin Transl Gastroenterol
February 2022
Immunovia, Inc., Marlborough, Massachusetts, USA.
Article Synopsis
- - The IMMray PanCan-d test, which combines biomarkers and CA19-9, aims to detect pancreatic ductal adenocarcinoma (PDAC) in blood samples, including those from individuals who can't express CA19-9.
- - In a study involving 586 participants, the test showed 98% specificity and between 85-87% sensitivity for detecting different stages of PDAC compared to high-risk individuals and healthy controls.
- - Excluding samples from individuals believed to be Lewis-null improved the test's sensitivity to 92% while maintaining a high specificity of 99%, highlighting its effectiveness in detecting PDAC.
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms.
Pancreatology
August 2021
Pancreatic Surgery Unit, Humanitas Clinical and Research Center - IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Background: Ampullary carcinoma (AC) is histologically classified as intestinal (In-AC), pancreaticobiliary (Pb-AC) or mixed-AC. The prognostic role of AC subtypes has been debated and remains unclear. The aims of this study were to evaluate outcomes after pancreatoduodenectomy (PD) for each subtype of AC and to compare these with pancreatic ductal adenocarcinoma [PDAC] and distal cholangiocarcinoma [DCC].
View Article and Find Full Text PDFIncidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012.
J Surg Oncol
March 2019
Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
Background And Objectives: Periampullary adenocarcinoma (PAC) is stratified anatomically: ampullary adenocarcinoma (AA), distal cholangiocarcinoma (DCC), duodenal adenocarcinoma (DA), and pancreatic ductal adenocarcinoma (PDAC). We aimed to determine differences in incidence, prognosis, and treatment in stage-matched PAC patients in a longitudinal study.
Methods: PAC patients were identified in The National Cancer Database from 2004 to 2012.
Clinicopathological Stratification and Long-term Follow-up of Patients with Periampullary Carcinomas.
Anticancer Res
September 2018
Department of Surgery, Charité University of Medicine Berlin, Berlin, Germany.
Background: Periampullary carcinomas generally confer a poor outcome. Choosing the most effective treatment regimen for each sub-entity proves challenging and is usually based on experience from pancreatic adenocarcinoma (PDAC).
Patients And Methods: The long-term follow-up is presented of 472 patients with periampullary tumors [PDAC, distal cholangiocarcinoma (dCC) and ampullary carcinomas (AC)] who underwent radical resection considering clinical characteristics, paraclinical findings and histopathological features in order to define factors of prognostic relevance.
The true prognosis of resected distal cholangiocarcinoma.
J Surg Oncol
April 2016
Service de Chirurgie Hépatobiliaire et Digestive, CHU Rennes, Rennes, France.
Background: Prognosis of distal cholangiocarcinoma (DCC) after pancreaticoduodenectomy (PD) remains poorly assessed. The aims of this study were to describe the oncological results of PD in DCC and to compare its prognosis to pancreatic ductal adenocarcinoma (PDAC).
Methods: All PD for periampullary carcinoma performed between January 2000 and March 2013 were extracted from a prospective database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!